FIELD: medicine.
SUBSTANCE: claimed group of inventions relates to medicine, in particular to therapy and immunology, and deals with treatment of vasculitis, induced by antineutrophilic cytoplasmatic antibodies (ANCA-associated vasculitis). For this purpose CD20-antibody is introduced in dose 400-1300 mg as monotherapy or in addition to therapy with steroids and immunosuppressants. CD20-antibody is introduced from one to three times during a month with further repeated introduction at stage of complete or partial remission.
EFFECT: mode of antibody introduction ensures efficient treatment and reduction of side effects due to reduction of dose or complete withdrawal of steroids and immunosuppressants.
117 cl, 8 ex, 4 tbl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
| VERSIONS OF IMMUNOGLOBULINS AND ITS APPLICATION | 2003 |
|
RU2326127C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
| ANALYSIS OF NEUTRALISING ANTIBODIES AND ITS APPLICATION | 2004 |
|
RU2370775C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
